Any concurrent chemotherapy, immune therapy, biologic, hormonal therapy for cancer treatment
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for the current colon cancer except for one cycle of mFOLFOX
Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, anti-cancer surgery or other anti-cancer therapy while on this protocol
Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, intravesical chemotherapy, surgery, or other therapy while on this protocol
Patients must not be planning to receive concomitant biologic therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study
Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Biologic therapy
. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic therapy for cancer treatment. Concurrent use of hormones for non-cancer related conditions is acceptable (e.g., insulin for diabetes & hormone replacement therapy). Local treatment of isolated lesions for palliative intent is acceptable;
Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within  weeks prior to initiation of DHESA
Prior biologic therapy:\r\n* Patients must have discontinued all biologic or investigational therapy at least  days before registration
Has received the prohibited therapy (e.g., concurrent anti-cancer therapy including but not limited to: chemotherapy, radiation, hormonal, or immunotherapy) ? days prior to first planned dose of ACMA.
Prior therapy: Patients must have discontinued all chemotherapy, investigational therapy or biologic therapy at least  days prior to initiating study treatment (with the exception of trastuzumab for patients with HER+ breast cancer)
Subject has received anti-cancer chemotherapy, immunotherapy, hormonal (with the exception of hormones for thyroid conditions or estrogen replacement therapy [ERT], or any investigational therapy) within  days of enrollment
Subjects must not have had prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.
Any prior anti-cancer chemotherapy, biologic or investigational therapy for PDAC.
Concurrent anticancer therapy (e.g. chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy, investigational therapy)
No prior chemotherapy, biologic therapy, hormonal therapy or investigational therapy for this operable breast cancer
Patients who are currently being treated with cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) other than the trial therapy.
Patients receiving other treatment for breast cancer (includes standard hormonal therapy, chemotherapy, biologic therapy, immunotherapy, or radiation therapy). Patients receiving chronic bisphosphonate or denosumab therapy are eligible.
Has received chemotherapy, immunotherapy, biologic therapy or endocrine therapy within the past  weeks
No concurrent anticancer therapy. Required washout from prior therapy:\r\n* Endocrine therapy: no required wash-out\r\n* Chemotherapy:  days\r\n* Major surgery:  days (provided wound healing is adequate)\r\n* Radiation:  days\r\n* Investigational/biologic therapy (half-life =<  hours):  days\r\n* Investigational/biologic therapy (half-life >  hours):  days.
Patients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol.
Is receiving concurrent chemotherapy, investigational drug, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer-related conditions (e.g., hormone replacement therapy) is acceptable.
Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterolacetate], or immunotherapy) =<  days prior to treatment with osimertinib
Patients receiving any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer (concurrent use of hormones for noncancer-related conditions [e.g., insulin for diabetes and hormone replacement therapy] is acceptable) Patients must have completed any previous cancer-related treatments before enrolment. The following intervals between the end of the prior treatment and first dose of study drug must be observed:
Any anticancer therapy within  days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not considered cancer therapy for the purpose of this protocol)
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment
Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment; concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable
Concurrent anticancer non protocol directed therapy (e.g. chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy, investigational therapy)
have received chemotherapy, hormonal therapy, biologic therapy, immunotherapy or radiation therapy within  days prior to the planned start of study treatment.
Any concurrent chemotherapy, investigational product (IP), biologic or hormonal therapy for cancer treatment; concurrent use of hormonal therapy for non-cancer-related conditions (e.g. hormone replacement therapy) is acceptable
Any of the following for the treatment of cancer within  weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy, or biologic therapy
Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, immunotherapy, or biologic therapy, including investigational agents for their disease
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Prior systemic therapy (chemotherapy, biologic, or immunotherapy) for the same OPSCC. Prior chemotherapy, biologic therapy, and radiotherapy is allowed in patients with loco-regional recurrent disease, if administered at least  months prior to study enrolment
Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) =<  days prior to treatment
Prior biologic therapy: Patients must have discontinued all biologic therapy at least  days before registration
Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within  weeks prior to the first dose of the study drug
Ongoing radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy directed at the tumor; those patients with a plexiform neurofibroma requiring treatment will be eligible
Patients receiving other concurrent cancer therapy including chemotherapy, immunotherapy, or biologic therapy
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Prior or concurrent systemic anticancer therapy for BC (immunotherapy, hormonotherapy, biologic/targeted therapy, chemotherapy, investigational agents).
Participant has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of  half-lives, prior to the first dose of ABBV- or Rovalpituzumab Tesirine.
Concurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiation therapy, standard or investigational
Patients must be at least  weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, immunotherapy and monoclonal antibodies, alternative therapy or investigational therapeutic agents); there is no limitation on the amount of prior therapies allowed; patients with ovarian cancer  weeks from previous therapy have been found to have normal monocyte function (unpublished)
Prior radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for prostate cancer
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable
Any concurrent chemotherapy, biologic or hormonal therapy for cancer treatment is not permitted within  days of registration\r\n* Note: Prior immunotherapy is not permitted\r\n* Note: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
NO prior chemotherapy, radiation therapy or biologic/targeted therapy for current diagnosis of lung cancer
Any concurrent chemotherapy, immunotherapies or biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable; in addition, local treatment (eg, by local surgery or radiotherapy) of isolated lesions for palliative intent is acceptable beyond the first cycle with prior consultation and in agreement with the principal investigator (PI)
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g. insulin for diabetes and hormone replacement therapy) is acceptable
Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, concurrent use of hormonal therapy for noncancer-related conditions (e.g., hormone replacement therapy) is acceptable
Is currently participating and receiving study therapy or concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment at the time of administration of first dose of trial treatment; continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotrophin releasing hormone [GnRH] agonist), ovarian, or breast cancer are not exclusionary
Concurrent treatment with any anticancer agent, including chemotherapy, immunotherapy, or biologic therapy; in breast cancer patients, concurrent use of hormonal therapy (but not trastuzumab) is acceptable provided hormonal therapy was initiated more than  days prior to treatment on this study
Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within  weeks prior to the first dose of the study drugs
Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within  weeks prior to the first dose of the study drugs
Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or hormonal therapy).
Subject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of  days or herbal therapy within  days prior to the first dose of ABBV-.
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)
Must be at least  days since last chemotherapy or biologic therapy administered; for patients previously enrolled on this trial who had a usable T cell product generated but removed prior to receiving T cell therapy and are re-enrolling on the trial, the time from chemotherapy agent or biologic agent is not restricted
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Patients who have had any prior treatment for CLL, including chemotherapy, corticosteroids, biologic therapy, or immunotherapy are NOT eligible for participation
Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within  days prior to Cycle  Day 
Patients taking any other concurrent approved or investigational anti-cancer therapy (e.g. chemotherapy, immunotherapy, targeted or biologic therapy)
Last dose of chemotherapy, immunotherapy, biologic therapy, or investigational therapy, was less than  days prior to protocol therapy (radiation and veliparib)
Patients must have completed any previous cancer-related treatments before enrolment. Any concurrent chemotherapy [Chemotherapy washout within  days or  half-lives (whichever is shorter) from enrolment], radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer excludes the patient (concurrent use of hormones for noncancer-related conditions [eg, insulin for diabetes and hormone replacement therapy] is acceptable),
Radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within the  days prior to day  of study drug\r\n* For the NSCLC expanded cohort only: palliative radiation therapy =< days of day  of study drug
Participant has received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy) prior to Study Day
Subject is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment; Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes) is acceptable
Has any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for invasive malignancy within  years. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.
At the time of enrollment, subjects may not have had any prior systemic therapy for breast cancer, including chemotherapy, targeted biologic therapy, or greater than  months of hormonal therapy; similarly, chemotherapy or biologic therapy must not be part of the subsequent treatment plan
Antineoplastic therapy (e.g. chemotherapy or targeted therapy) for other invasive cancer within  years before randomization; (for the purposes of this study, hormonal therapy is not considered chemotherapy)
Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer
Concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, hormonal therapy, or any other biologic therapy)
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
Patient must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol treatment
Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment
Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, surgery or other therapy after step  registration
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Patients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancer
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Any anticancer therapy, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not considered cancer therapy for the purpose of this protocol)
Use of hormonal therapy or biologic therapy for prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist therapy) or use of an investigational agent within  weeks of randomization;
Subject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of  days or anti-cancer herbal therapy within  days prior to Cycle  Day  of ABT-.
Concurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiation therapy, standard or investigational
Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within  weeks of the first dose of study drug
Receiving concurrent chemotherapy, biologic therapy, radiotherapy, or other investigational therapy
Patients may not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study other than hydroxyurea for control of counts
Prior use of anti-HER therapy for any reason or other prior biologic or immunotherapy for cancer
Radiation therapy, hormonal therapy, biologic therapy, experimental therapy, or chemotherapy for cancer =<  days prior to registration
Are receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than % of the bone marrow or with a wide field of radiation within  weeks prior to enrollment.
Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within  weeks prior to the first dose of the study drugs
Any concurrent chemotherapy, investigational product , biologic, or hormonal therapy for cancer treatment.
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Patient must not have received any cancer-directed therapy (e.g., surgery, chemotherapy, radiation therapy, biologic therapy) for the index diagnosis
Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment;
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
Any investigational agent, chemotherapy, immunotherapy, biologic, hormonal within  days of the first dose of study treatment
Patients who have received prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy, hormonal therapy) within  weeks prior to registration are not eligible for participation
Prior chemotherapy or biologic therapy for the same HNSCC; prior chemotherapy or biologic therapy for a different previous HNSCC is allowed
Any prior chemotherapy, radiation therapy, or biologic therapy (targeted therapy) for treatment of the patients pancreatic tumor
Patient must not have had chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or investigational therapy within  days or  half-lives of the drug prior to the first dose of pazopanib; for patients enrolling in the phase I portion of this study, this requirement does not apply to prior treatment with cetuximab
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.
Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic therapy for advanced or metastatic disease with the following exceptions:
Biologic therapy: ?  weeks
Anti-Cancer therapy including chemotherapy, radiation-therapy, immunotherapy, biologic therapy or major surgery within  days prior to start of study treatment (Note: Dabrafenib monotherapy within  days prior to starting combination therapy is allowed for crossover subjects in Cohort A);
Concurrent or planned radiation, hormonal, chemotherapeutic, experimental or targeted biologic therapy
Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ARQ 
Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer
Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, or immunotherapy
Received anti-cancer therapy including chemotherapy, immunotherapy, radiation, biologic, any investigational therapy or herbal therapy within a period of  days prior to the first dose of ABBV-, and have unresolved toxicities ? grade 
Patients may not have received any prior chemotherapy, biologic therapy or radiation therapy for management of their disease; chemotherapy or biologic therapy administered for treatment of another primary malignancy are permitted if treatment was greater than  years ago
Patients who are receiving any chemotherapy, biologic therapy, radiation therapy or any investigational agent
Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment
No prior treatment (irradiation, chemotherapy, hormonal, immunotherapy or investigational, etc.) for breast cancer excluding therapy for ductal carcinoma in situ (DCIS); subjects receiving hormone replacement therapy (HRT) are eligible if this therapy is discontinued at least  weeks before starting study therapy
Other concurrent anti-tumor, chemotherapy, hormonal therapy, immunotherapy regimens or radiation therapy, standard or investigational
Concomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.
Concomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.
At least  weeks since the last previous cancer treatment including: chemotherapy, radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics.
Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer; patients with history of breast cancer greater than  years from initial diagnosis are eligible for the study; patients may not have received anthracycline-based chemotherapy in the past; patients with history of ductal carcinoma in situ (DCIS) are eligible if there were treated with surgery alone
Patients must not have had major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within  weeks prior to entering the study and must have evidence of stable or progressive disease to be eligible
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) for the treatment of Stage IV non-squamous NSCLC
Concomitant chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapy
Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, receipt of last dose of an approved anticancer therapy within  days
Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within  weeks prior to initiation of DLYEA
Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.
Fewer than  days since last anti-tumor therapy, including chemotherapy, biologic except trastuzumab, experimental, immune, radiotherapy for the treatment of breast cancer, with the following exceptions:\r\n* Hormone therapy \r\n* Palliative radiation therapy involving =< % of marrow-bearing bone is allowed if completed within >=  days prior to first study treatment
No concurrent systemic chemotherapy or anticancer biologic therapy is allowed. Note: Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study.
The subject has received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy within a period of  days prior to the first dose of ABT-.
Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, immunotherapy, or biologic therapy
Treatment with prohibited medications (eg, concurrent anti-cancer therapy including other chemotherapy, radiation (local radiation for palliative care is permitted), hormonal anti-cancer treatment, biologic therapy, or immunotherapy) <  days prior to the first day of study treatment
Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment
Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) before Day  of Cycle  for the treatment of advanced (Stage IV) or recurrent NSCLC
Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal therapy for treatment of lymphoma within  days prior to treatment
Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment
Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer
Patients who have received prior chemotherapy, immunotherapy, radiotherapy, hormonal therapy or biologic therapy for their ovarian or primary peritoneal cancer are not eligible
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy).
No prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer
Concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapy for treatment of cancer;
Use of chemotherapy, biologic therapy, radiation therapy, erythropoietin or related erythropoiesis stimulating agents, or investigational therapy within  weeks of the first dose of study drug
Be receiving any form of treatment for cancer with the exception of hormonal or biologic therapy
Have not received chemotherapy or radiation for >  days (advanced cancer patients receiving hormonal therapy, immunotherapy, or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible)
Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment Active or prior documented autoimmune disease with some exceptions.
Treatment with chemotherapy, immunotherapy, or biologic therapy as anti-cancer therapy within  weeks, or treatment with endocrine therapy or kinase inhibitors within  weeks, prior to starting study treatment, except for premenopausal participants with breast cancer who may continue Gonadotropin-releasing hormone agonist therapy
Patients must not be planning to receive other biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other therapy while on this protocol; palliative radiation therapy or surgery can be considered for symptomatic non-target lesions after discussions with the study team
Expected to require cancer treatment, other than biologic or hormonal maintenance therapy, during the course of the study
Patients must not have received prior radiation therapy, systemic chemotherapy, immunotherapy, therapy with biologic agents or hormonal therapy for their brain tumor
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.
Close proximity in time to treatment with high-dose chemotherapy, stem-cell rescue, differentiation therapy, immunotherapy, thoracic or mediastinal radiotherapy, hormonal therapy, biologic therapy, herbal cancer therapy, hematopoietic growth factor, investigational therapy, or St. John's wort according to protocol-defined criteria prior to initiation of study drug
No prior treatment involving irradiation, hormonal therapy, immunotherapy, investigational therapy, and/or other concurrent agents or therapies for ovarian cancer
Participant has received anti-cancer therapy including chemotherapy, immunotherapy, biologic or any investigational therapy within a period of  days prior to Study Day
Concomitant biologic, hormonal, or radiation therapy are acceptable
Patients who are planned to receive either chemotherapy, targeted therapy, immunotherapy, or no additional cancer-directed drug therapy
Received treatment with chemotherapy, radiation, or biologic cancer therapy within  days of first protocol treatment; prior and concurrent hydroxyurea is permitted
Patients cannot have hormonal cancer therapy or radiation therapy as prior cancer treatment within  years of registration; (prior surgery, biologic therapy, hormonal therapy, or radiation therapy for a malignancy over  years prior to enrollment that is not considered cured is acceptable)
Chemotherapy, biologic therapy, radiation therapy or immunotherapy within  weeks prior to dosing with amatuximab
Patients must be registered prior to or on the same day as their first cycle of chemotherapy for their current disease and stage (or disease setting); patient must not have had any systemic therapy (chemotherapy or combination regimens) in the  days just prior to registration; prior biologic therapy, immunotherapy, and hormonal therapy are allowed
Completion of prior chemotherapy, biologic therapy, immunotherapy, or radiation therapy at least  weeks prior to enrollment.
The participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy (RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.
The participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy,radiation therapy ( RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.
